Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003649 · ClinicalTrials.gov registry record · Phase 1
Gene Therapy in Treating Patients With Non-small Cell Lung Cancer That Cannot Be Surgically Removed
A Phase 1 study, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00003649: Completed Phase 1 study, sponsored by Eastern Cooperative Oncology Group.
NCT00003649 is a Phase 1 study that has completed, run by Eastern Cooperative Oncology Group. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003649, a Phase 1 study, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Exposing tumor cells to the p53 gene may improve the body's ability to fight non-small cell lung cancer. PURPOSE: Phase I trial to study the effectiveness of gene therapy in treating patients who have non-small cell lung cancer that cannot be surgically removed.
Interventions
- BIOLOGICAL Ad5CMV-p53 gene
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-11-17 |
| Est. Completion | 2007-06-15 |
| Phase | Phase 1 |
What the finished NCT00003649 record still lists
NCT00003649 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Ad5CMV-p53 gene is the first listed.
NCT00003649 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00003649 about?
NCT00003649 is a clinical study titled "Gene Therapy in Treating Patients With Non-small Cell Lung Cancer That Cannot Be Surgically Removed". RATIONALE: Exposing tumor cells to the p53 gene may improve the body's ability to fight non-small cell lung cancer. PURPOSE: Phase I trial to study the effectiveness of gene therapy in treating patients who have non-small cell lung cancer that cannot be surgically removed.
What is the current status of trial NCT00003649?
This trial is currently completed. It is a Phase 1 study. The study started on 1998-11-17. Estimated completion is 2007-06-15.
What interventions are being tested in trial NCT00003649?
The interventions under investigation include: Ad5CMV-p53 gene (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003649?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI